Tela Bio Inc logo

Tela Bio Inc(TELA)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.82
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for TELA

11/13/2026: TELA (1-star) is currently NOT-A-BUY. Pass it for now.

Tela Bio Inc is a medical technology company specialized in innovative soft-tissue reinforcement materials for hernia and plastic surgery. The company is known for its proprietary OviTex platform, which focuses on delivering superior clinical outcomes compared to legacy synthetic meshes. Its growth story hinges on successfully expanding its direct sales force and capturing market share in the multi-billion dollar reconstructive surgery market. Primary risks include intense competition from large incumbents, consistent operating losses, and execution challenges in scaling its business. Tela Bio may suit growth-oriented investors looking for exposure to clinical innovation, while prospective shareholders should monitor clinical data releases and progress toward profitability.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company is in an early-to-mid commercialization phase with significant potential to displace legacy products.
Momentum investorMixed fitMomentum is conditional on positive commercial milestones or clinical data updates that drive stock price volatility.
Value investorWeak fitThe company is not currently profitable, making traditional value metrics like P/E ratios inapplicable.
Dividend investorWeak fitTela Bio is a high-growth company that retains all earnings for operations.
Low-risk investorWeak fitHigh market volatility and operational risks make this unsuitable for low-risk portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock is subject to sharp price fluctuations typical of small-cap medical technology firms.
Valuation riskMedium / highValuation is sensitive to long-term growth expectations rather than current earnings.
Competition risk (BD and legacy mesh)HighDominant competitors have the resources to defend their market share aggressively.
Business qualityMediumWhile the technology is innovative, the company is still building the necessary scale for sustainable profitability.
Dividend incomeLow / noneThe company does not pay a dividend.
Execution riskMedium / highSuccess relies heavily on continued adoption by surgeons and effective sales force execution.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 37.06M USD
Price to earnings Ratio -
1Y Target Price 1.8
Price to earnings Ratio -
1Y Target Price 1.8
Volume (30-day avg) 148.2K shares
Beta 1.46
52 Weeks Range 0.50 - 1.50
Updated Date 11/14/2026
52 Weeks Range 0.50 - 1.50
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.74

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit -3.39%
Avg. Invested days 28
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
TELA receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
TELA has moderate overall fundamentals (3 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, solid revenue growth (+15.8%) is partially offset by slightly negative earnings growth (-2.6%), weak cash generation (FCF margin -35.7%), weak profitability (net margin -48.4%).

Financial Health Rating

★★★★★
TELA's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 70.8%). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is TELA's strongest growth driver at +32.7% FY2025 versus FY2024 (solid, 4 stars). By comparison, revenue growth (+15.8%, solid) is also solid, while earnings growth (-2.6%, slightly negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 67.9% and approximately 47.3% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 7.18% supports management-shareholder alignment.

Top 5 Institutional Investors

Nantahala Capital Management, LLC 26.11%
Essex Woodlands Health Ventures 17.09%
Stonepine Capital Management Llc 5.90%
SILVERARC CAPITAL MANAGEMENT, LLC 4.73%
Vanguard Capital Management, LLC 3.47%

Unit Economics (Per $1K Revenue)

★★★★★
TELA generates approximately $677 of gross profit, $-420 of operating income, and $-357 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.60% (Tax Credit)

Quantitative Style Profile

★★★★★
TELA has a Value-Oriented profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Soft Tissue RepairRevenue generated from the sale of OviTex and OviTex PRS mesh products to hospitals and surgery centers.The company makes money by convincing surgeons to choose its advanced mesh products for hernia and reconstruction surgeries.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 73.93M
Price to Sales(TTM) 0.47
Enterprise Value 73.93M
Price to Sales(TTM) 0.47
Enterprise Value to Revenue 0.95
Enterprise Value to EBITDA -5.01
Shares Outstanding 45.19M
Shares Floating 21.35M
Shares Outstanding 45.19M
Shares Floating 21.35M
Percent Insiders 7.18
Percent Institutions 67.86

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.